pAc-Neo-OVA Citations (3)

Originally described in: Introduction of soluble protein into the class I pathway of antigen processing and presentation.
Moore MW, Carbone FR, Bevan MJ Cell. 1988 Sep 9. 54(6):777-85. PubMed Journal

---

Articles Citing pAc-Neo-OVA

Articles
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, Levine BL, Kalos M, Czerniecki BJ, Torigian DA, Powell DJ Jr, Mick R, Coukos G. Clin Cancer Res. 2013 Sep 1;19(17):4801-15. doi: 10.1158/1078-0432.CCR-13-1185. Epub 2013 Jul 9. PubMed
Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites. Martin AL, Powell C, Nagy MZ, Innamarato P, Powers J, Nichols D, Anadon CM, Chaurio RA, Kim S, Wang MH, Gong B, Wang X, Scheutz TJ, Antonia SJ, Conejo-Garcia JR, Perez BA. Cancer Immunol Immunother. 2022 Dec 5. doi: 10.1007/s00262-022-03325-y. PubMed
IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma. Montoya M, Collins SA, Chuntova P, Patel TS, Nejo T, Yamamichi A, Kasahara N, Okada H. bioRxiv [Preprint]. 2024 Apr 3:2024.04.02.587608. doi: 10.1101/2024.04.02.587608. PubMed

If you have published an article using this material, please email us at to have your article added to this page.